Newsroom

February 16, 2022 in Press Release

SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline

Financing co-led by UCB Ventures and Ysios Capital with participation by New Enterprise Associates, Gilde Healthcare, Novartis Venture Fund and Asabys Partners Unique Protein Splicing platform enables efficient delivery of…
Read More
January 21, 2021 in Press Release

Splice Bio appoints Jean-Philippe Combal as Chairman of the Board of Directors

BARCELONA, January 21, 2021 – Splice Bio, a gene therapy company based on technology developed in the Muir Lab at Princeton University, announced today that it has appointed Jean-Philippe Combal…
Read More
December 10, 2020 in Press Release

Splice Bio announces research funding by Cystic Fibrosis Foundation to develop novel AAV vectors

BARCELONA, December 10, 2020 – Splice Bio, a biotech company based on technology developed in the Muir Lab at Princeton University, announced today a research agreement with the Cystic Fibrosis…
Read More
October 20, 2020 in Press Release

Splice Bio awarded with a “RETOS de Colaboración” grant

BARCELONA, October 20, 2020 – Splice Bio, a biotech company based on technology developed in the Muir lab at Princeton University, announced today that it has been awared a “RETOS-Colaboración”…
Read More
September 15, 2020 in Press Release

ProteoDesign announces new Investment led by Ysios Capital and rebrands as Splice Bio

ProteoDesign rebrands as Splice Bio to develop novel gene therapies based on its proprietary intein technology. This pioneering platform has the potential to target genetic diseases that cannot be addressed…
Read More